Exicure (XCUR) Income from Continuing Operations (2016 - 2026)
Exicure (XCUR) reported Income from Continuing Operations of 1828000.0 for Q1 2026, down 160.73% on a YoY basis from 3010000.0 in Q1 2025, and up 36.92% quarter-over-quarter from 2898000.0 in Q4 2025.
Exicure (XCUR) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Exicure has reported Income from Continuing Operations for 11 years, with the latest figure at 1828000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 160.73% year-over-year to 1828000.0; the trailing twelve-month figure through Mar 2026 stood at 9784000.0 (down 66.91% YoY), and the FY2025 full-year result was 4946000.0, up 49.02% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1828000.0, up from 2898000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 18396000.0 in Q4 2022, with the low at 8348000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 2115941.18 across 5 years, with a median of 2621000.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 382.92% — and 2025, when it jumped 463.09%.
- Exicure's Income from Continuing Operations stood at 18396000.0 in 2022, then slumped by 108.08% to 1487000.0 in 2023, then sank by 382.92% to 7181000.0 in 2024, then jumped by 59.64% to 2898000.0 in 2025, then surged by 36.92% to 1828000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1828000.0 (Q1 2026), 2898000.0 (Q4 2025), and 2437000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Exicure | 19.38 Mn | 16.77 Mn | - | -1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.83 Mn |
| Dec 31, 2025 | -2.90 Mn |
| Sep 30, 2025 | -2.44 Mn |
| Jun 30, 2025 | -2.62 Mn |
| Mar 31, 2025 | 3.01 Mn |
| Dec 31, 2024 | -7.18 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -600,000.00 |
| Mar 31, 2024 | -829,000.00 |
| Dec 31, 2023 | -1.49 Mn |
| Sep 30, 2023 | -5.26 Mn |
| Jun 30, 2023 | -5.76 Mn |
| Mar 31, 2023 | -4.41 Mn |
| Dec 31, 2022 | 18.40 Mn |
| Sep 30, 2022 | -5.16 Mn |
| Jun 30, 2022 | -7.47 Mn |
| Mar 31, 2022 | -8.35 Mn |
| Dec 31, 2021 | -13.83 Mn |
| Sep 30, 2021 | -23.53 Mn |
| Jun 30, 2021 | -14.27 Mn |